Found 4353 articles for: ""
Novel Clinical Applications of Topical Ruxolitinib: A Case Series
March 2024 | Volume 23 | Issue 3 | Case Reports | 188 | Copyright © March 2024
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatiti...
Read MoreExamining the Uncertainties Surrounding Exosome Therapy in Androgenetic Alopecia: A Call for Evidence-Based Practice
March 2024 | Volume 23 | Issue 3 | Features | e86 | Copyright © March 2024
Hair loss, a pervasive and often distressing condition, affects a substantial number of individuals globally. Although conventional treatments such as hair transplantation, topicals, oral medicat...
Read MoreUrticaria Pigmentosa Without Pruritus
March 2024 | Volume 23 | Issue 3 | Case Reports | e81 | Copyright © March 2024
Mastocytosis is a group of disorders characterized by the pathologic accumulation of mast cells in various tissues. One example of mastocytosis is urticaria pigmentosa, which presents with mastoc...
Read MoreEfficacy and Tolerability of Topical 0.1% Stabilized Bioactive Retinol for Photoaging: A Vehicle-Controlled Integrated Analysis
April 2024 | Volume 23 | Issue 4 | Original Article | 209 | Copyright © April 2024
Read MoreFirst Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis
March 2024 | Volume 23 | Issue 3 | Case Reports | 192 | Copyright © March 2024
Plaque psoriasis is a chronic, immune-mediated, cutaneous, and systemic inflammatory dermatosis. Its pathogenesis involves the dysregulation of the interleukin (IL)-23/IL-17 signaling pathway. Th...
Read MoreINDIVIDUAL ARTICLE: Antibiotic Stewardship in Acne: 2023 Update
February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF378969s4 | Copyright © February 2024
Antibiotics, topical and oral, are a cornerstone in the treatment of acnes vulgaris specifically by targeting the skin bacterium Cutibacterium acnes. Billions of individuals have received antibio...
Read MoreFULL SUPPLEMENT: Looking Beyond the Skin, Examining the Patient and Clinician Reported Outcomes and Effects of Acne Vulgaris and Sarecycline Treatment
February 2024 | Volume 23 | Issue 2 | Department | SF405634s1 | Copyright © February 2024
Background: Concise patient-reported outcome (PRO) instruments addressing the consequences of facial acne vulgaris (AV) on patients' functioning and activities of daily living (A...
Read MoreFULL SUPPLEMENT: Updating Antibiotic Use for Acne Management in 2023
February 2024 | Volume 23 | Issue 2 | Department | SF378969s1 | Copyright © February 2024
Antibiotics, topical and oral, are a cornerstone in the treatment of acnes vulgaris specifically by targeting the skin bacterium Cutibacterium acnes. Billions of individuals have received antibio...
Read MoreINDIVIDUAL ARTICLE: Vehicles Matter!
February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF378969s3 | Copyright © February 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study
February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF405634s12 | Copyright © February 2024
Background: Patient-reported outcomes (PROs) are emerging as a fundamental component of disease impact assessment in acne vulgaris (AV), complementing clinician-reported outcomes...
Read MoreINDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study
February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF405634s5 | Copyright © February 2024
Background: Concise patient-reported outcome (PRO) instruments addressing the consequences of facial acne vulgaris (AV) on patients’ functioning and activities of daily liv...
Read MoreINDIVIDUAL ARTICLE: Assessing the Impact of Acne and Its Treatment on Disease Burden and Quality of Life
February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF405634s4 | Copyright © February 2024
Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 50 | Copyright © February 2024
Introduction: Moisturizers are often used as adjuvant therapy for psoriasis to assist with rehydration and skin barrier restoration. Fixed-combination halobetasol propionate 0.01...
Read MoreBenefit of Topical Combination Therapy for Acne: Analyzing Effect Size Using Number Needed to Treat
February 2024 | Volume 23 | Issue 2 | Original Article | 42 | Copyright © February 2024
Background: Topical acne trials often are confounded by high vehicle response rates and differing outcome measures, making it difficult to compare treatments. Number needed to tr...
Read MoreSensitive Skin: A Survey of Dermatology Resident Physicians' Perspectives and Educational Exposures
February 2024 | Volume 23 | Issue 2 | Original Article | 85 | Copyright © February 2024
Sensitive skin (SS) is a common patient complaint presenting to the dermatology office, but there exists a lack of consensus on defining criteria and evidence-based management approaches. Further...
Read MoreWhat's Old Is New: An Emerging Focus on Dermatoporosis
February 2024 | Volume 23 | Issue 2 | Features | 113 | Copyright © February 2024
New Insights Into Systemic Drivers of Inflammation and Their Contributions to the Pathophysiology of Acne
February 2024 | Volume 23 | Issue 2 | Original Article | 90 | Copyright © February 2024
Read MorePerceptions, Utilization, and Cost Assessment of Sebaceous Hyperplasia Treatment Modalities: A Pilot Survey
February 2024 | Volume 23 | Issue 2 | Original Article | 29 | Copyright © February 2024
Background: Sebaceous hyperplasia (SH) is a common, benign but cosmetically bothersome skin condition preferentially affecting older adults. Despite multiple treatment options, t...
Read MoreThe Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients
February 2024 | Volume 23 | Issue 2 | Original Article | 78 | Copyright © February 2024
Immune checkpoint inhibitors (ICI) are widely utilized for the treatment of malignant melanoma. Interestingly, gastrointestinal microbiome composition has emerged as a predictive biomarker of imm...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Media and other results for: ""
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
